Profound Medical (PROF) said new data from a Level 1 evidence trial of its MRI-guided Tulsa procedure demonstrated statistically significant superiority over robotic radical prostatectomy in men with intermediate-risk prostate cancer.

At one month, patients treated with whole-gland Tulsa showed no median change in short-term physical outcomes, compared with a measurable reduction for robotic radical prostatectomy, the company said Friday in a statement.

The findings add to previously reported trial results showing the procedure was superior to robotic prostatectomy in preserving erectile function and urinary continence at six months, Profound Medical said.

Profound Medical shares rose 3.4% in Friday trading.

Price: 7.08, Change: +0.23, Percent Change: +3.36